At the well-controlled HbA1c of the participants, previous literature shows current diabetes treatments have similar HbA1c decreases, so the HbA1c mean difference of long half-life PDE5 inhibitors may ...

Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interest in their joint ...

However, isoform-selective targeting within highly conserved kinase families is a formidable challenge. In some kinase families, cysteines are present in only one isoform, providing a strategy for ...

--Revolution Medicines, Inc., a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc., a biopharmaceutical ...

Phosphatidylinositol 3-kinases (PI3Ks) are a family of enzymes that catalyze the phosphorylation of phosphatidylinositol at the D-3 position of the inositol ring, serving critical functions in ...

Celastrol has been identified as a reactive oxygen species (ROS) elevator that reduces cancer cell proliferation by inhibiting peroxiredoxin (PRDX) activity, albeit with poor selectivity. We describe ...

Methods: In the EDATE observational study, phosphodiesterase-type-5 (PDE5)-inhibitor pretreated or naïve ED patients who started or switched to TAD-OaD were prospectively followed for 6 months.